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weekly up to 100 days post-alloHSCT. Circulating myeloid
(CD11chi) and plasmacytoid (CD123hi) DCs were enumerated and
the expression of CMRF-44 was assessed on CD11chi DC by four
colour ﬂow cytometry. Multivariate analyses were performed using
a non-parametric Mann-Whitney U-test and receiver operating
characteristic (ROC) curves. Following alloHSCT, the severity of
acute GVHD correlated with the number of total DC in the blood
(P  .035). Furthermore, low myeloid and plasmacytoid DC num-
bers were signiﬁcantly associated with grade 2-4 acute GVHD
(P  .046 and .017 respectively). In 40 alloHSCT patients, 27
developed acute GVHD. CMRF-44 was expressed on CD11c
DC in all cases prior to the onset of acute GVHD. Of the 13
patients without GVHD, 8 had no circulating CMRF-44
CD11cDC. CMRF-44 expression was independent of the recon-
stitution of myeloid DC (P  .73). Patients who had CMRF-44
CD11c DC in more than 20% of their post-transplant monitor-
ing samples were more likely to develop acute GVHD (P  .001,
OR  37.1). In addition, patients with more severe grade 2-4
GVHD had signiﬁcantly higher percentages of CMRF-44
CD11c DCs (P  .001). CMRF-44 expression at greater than or
equal to 12% of CD11chi DCs had a sensitivity of 87.5 for predic-
tion of grade 2-4 acute GVHD and a speciﬁcity of 91.7. We
conclude that CMRF-44 expression on blood CD11c DC is
highly associated with the onset of acute GVHD. The detection of
circulating activated DCs may be used as a predictive tool to
identify patients at risk of severe GVHD and potentially to direct
therapy. Our data also reinforces the potential for suitably engi-
neered CMRF-44 or other antibodies directed at DC activation
antigens to prevent or treat GVHD.
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DETERMINING PROGNOSIS FOR PATIENTS WITH ACUTE GVHD IN REAL
TIME: DEVELOPMENT AND TESTING OF AN ACUTE GVHD ACTIVITY
INDEX
McDonald, G.B.1, Leisenring, W.M.1, Martin, P.J.1 1Fred Hutchinson
Cancer Research Center, Seattle, WA.
The current scoring systems for acute GVHD are problematic
due to the retrospective assignment of scores, lack of consideration
for the efﬁcacy of treatment, and inter-observer error. An evi-
dence-based, real-time system for scoring GVHD would be useful
for determining prognosis in individual patients and for quantify-
ing the burden of GVHD across time.Methods:We examined the
severity of signs and symptoms of GVHD from its onset to day 100
in 386 patients with CML who underwent allogeneic transplant
after a myeloablative regimen. During each 10 day period to day
100, a unique letter designation was assigned for each degree of
abnormality in skin, liver, upper gastrointestinal tract, lower gas-
trointestinal tract, immunosuppressive drugs, fever, and perfor-
mance status, respectively. We used a training data set of 193
randomly selected patients, logistic regression methods, and re-
ceiver-operator curves for optimizing the model, to create an
activity index (aGVHDAI) that predicts non-relapse mortality at
day 200. Scaling was carried out by dividing the coefﬁcients in the
logistic regression model by the sum of the coefﬁcients and mul-
tiplying this proportion by 100. The ﬁnal aGVHDAI was then
applied to an independent, 193-patient data set, testing the accu-
racy of the index to predict day 200 non-relapse mortality. Results:
Parameters entering the optimal aGVHDAI model included the
level of jaundice, caloric intake, need for prednisone therapy, and
performance score. Skin GVHD, volume of diarrhea, and presence
of fever did not improve the model’s predictive ability (Table 1).
The area under a receiver-operator curve for the ﬁnal average
aGVHDAI model in the training data set, using non-relapse mor-
tality at day 200 as the end point, was 0.87. When the model was
then applied to an independent data set of 193 patients, the area
under an ROC curve was 0.85. Using the same aGVHD activity
index parameters, a graphic was developed that allows prediction of
non-relapse mortality at day 200 (on the vertical axis) for individual
patients, based on the aGVHDAI at any point in time after trans-
plant (on the horizontal axis). Conclusions: An acute GVHD
activity index has been tested that allows prediction of non-relapse mor-
tality in real-time and provides investigators with a research tool for
assessing the burden of acute GVHDover time. This aGVHDAI, scaled
from 0-100, is based on serum bilirubin levels, caloric intake, need for
prednisone therapy, and performance status.
Table 1. Components of the Acute GVHD Activity Index with
Weighting Factors for Each component
Factor Scoring Level
Scaled Weight-
ing Factor
Liver dys-
function
Total serum bilirubin 2–4 mg/
dL
16
Total serum bilirubin >5 mg/
dL
26
Upper GI
tract
Oral caloric intake <40%, with
poorly controlled anorexia,
nausea, or vomiting
20
Immuno-
suppressive
therapy
Any prednisone dose or
secondary therapy for
GVHD
17
Performance
status
Ambulatory but restricted in
strenuous activity
20
Limited self-care, more than
50% of time in bed, or worse
37
The scale is from 0 to 100, with the end point of day 200 non-
relapse mortality.
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THE CYTOKINE STORM AND ACUTE GRAFT-VERSUS-HOST DISEASE
(aGVHD) AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGE-
NEIC STEM CELL TRANSPLANTATION (allo-SCT)
Mohty, M.1, Gaugler, B.2, Faucher, C.1, Furst, S.1, Olive, D.2,
Blaise, D.1 1Institut Paoli-Calmettes, Marseille, France; 2INSERM
UMR 599, Marseille, France.
The use of RIC regimens has modiﬁed the natural history of
transplant-related complications, especially aGVHD. The aim of
this study was to investigate the role of inﬂammatory cytokines on
aGVHD incidence and severity in 113 patients who received a RIC
allo-SCT from an HLA-identical sibling. Plasma levels of 10 dif-
ferent cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, IL-18,
TNF-
, IFN-
, IFN-, and Fas-L) were measured by ELISA
prior to allo-SCT, at day 0 prior to graft infusion, and at regular
times within the ﬁrst 3 months after allo-SCT. Except for IL-
12p70, all measured cytokines showed little variations in the blood
in the ﬁrst three months after allo-SCT. The incidence of grade
II-IV aGVHD was 45% (95% CI, 36-54%; median onset, 32 days
after allo-SCT). In the subgroup of patients for whom all tested
cytokines could be measured closely, but rigorously prior to
aGVHD clinical onset, a high IL-12p70 level (P  104) was
signiﬁcantly associated with the development of clinically signiﬁ-
cant grade II-IV aGVHD. IL-12p70 levels were signiﬁcantly cor-
related to the severity of aGVHD: grade 0-I, median 468 pg/ml;
grade II, median 2538 pg/ml; and grade III-IV, median 4615
pg/mL (P  .0001). In patients experiencing grade II-IV aGVHD,
IL-12p70 levels decreased after aGVHD therapy. Interestingly, we
found a more rapid recovery of monocytes, the main pool of
IL-12p70-secreting myeloid dendritic cells (DC), prior to aGVHD
clinical onset in patients with grade II-IV aGVHD, as compared to
patients with grade 0-I aGVHD (median, 829/L vs. 552/L; P 
.005). At the effector level, we observed a signiﬁcantly more robust
recovery of genuine naive CD3CD4CD45RACD27 T
cells prior to aGVHD clinical onset, in patients with grade II-IV
aGVHD, as compared to patients with grade 0-I aGVHD (median,
50/L vs. 16/L; P  .006). In multivariate analysis, IL-12p70
level measured before aGVHD clinical onset was the strongest
predictive factor for aGVHD development and severity (P 104;
RR  10.7; 95% CI, 3.8-30.6). Overall, these ﬁndings reconstitute
a genuine Th1 loop, supporting a model where aGVHD primarily
reﬂects a type 1 alloreaction (rapid monocytes/DC recovery, IL-
Oral Presentations
13BB&MT
12p70 secretion, naive CD4 T cell expansion, Th1 and Tc1 cells
differentiation) in the context of RIC allo-SCT. The ﬁne functions
of immune effectors would tend to be more evident in such less
toxic regimens, offering new opportunities for a better understand-
ing of aGVHD pathophysiology and therapy.
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RAPAMYCIN ADDED TO HUMAN CD25 CELL CULTURES ACTIVATED
THROUGH CD3/CD28 ENRICHES FOR CD4CD25CD27Foxp3
REGULATORY T CELLS
Keever-Taylor, C.A., Browning, M.B., Johnson, B.D., Truitt, R.L.,
Behn, B.A. Medical College of Wisconsin, Milwaukee, WI.
CD4 T cells that constitutively express high levels of CD25
inhibit T-cell responses in a dose-dependent manner. Methods to
isolate and expand CD4CD25 regulatory T-cells (Tregs) have
been developed to allow for potential clinical use in regulating
undesired T cell-mediated responses such as autoimmune disease
or GVHD. We have enriched for Tregs by CD25 positive selec-
tion followed by culture in ex vivo 15-5% HS and autologous
feeder cells. Activation is through a single addition of CD3/CD28
Ab-linked beads (4:1 bead:cell) and IL-2 (100 U/mL added d 3).
Cultures with potent suppressor activity expanded on average 450
fold in 14 d when maintained at 5  105/mL in medium  IL-2.
However, by 21 d suppressor activity greatly diminished and the %
of CD25-bright cells decreased, indicating activated non-Treg
cells were dominating the cultures. To increase the purity of Tregs
we explored the use of rapamycin, a T cell immunosuppressive
agent recently shown to selectively spare murine Tregs. Rapamy-
cin (20-0.01 ng/mL) added to CD25-enriched cells signiﬁcantly
inhibited cell expansion at doses 1 ng/mL that was inversely
correlated with enhanced suppressor activity at days 10 and 21.
Cultures without rapamycin expanded on average 17,000 fold by
day 21 vs 350 fold with 1 ng/mL rapamycin. By 21 d cells from
untreated cultures suppressed allo-proliferation by only 28% at a
1:1 suppressor:responder ratio compared to 63  20% by cells
grown in 1 ng/mL rapamycin (P  .007). The %
CD4CD25bright cells at 10 d and 21 d was higher in rapamycin-
containing cultures than untreated cultures, P  .003. Intracellular
FACS staining for the transcription factor Foxp3, a marker for
Tregs, showed signiﬁcantly higher expression on CD4 cells from
10 d rapamycin containing cultures with 23  6% Foxp3CD4
cells vs 5  3% in cultures without rapamycin (P  .03, n  4).
Foxp3 was predominately expressed on CD4CD25-bright cells
that also co-expressed CD27-bright. By day 21 cultures grown in
rapamycin contained 1000 to 5000 fold more CD4Foxp3 cells
than 10 d cultures without rapamycin. Only 0.7% of CD4 cells
from CD4CD25-neg cells cultured with rapamycin expressed
Foxp3. Optimal Foxp3 expression required continued presence of
rapamycin in culture and addition at culture initiation was superior
to addition at day 3. In summary, addition of rapamycin at doses
from 1-20 ng/mL to CD25-enriched cell cultures increased the
purity of cells with the phenotype and function of Tregs.
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PROSPECTIVE EVALUATION OF A GvHD-SPECIFIC PROTEOMICS PAT-
TERN AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Weissinger, E.M.1, Hillmann, M.2, Dammann, E.1, Kolb, H.-J.3,
Holler, E.4, Mischak, H.2, Ganser, A.1, Hertenstein, B.5 1Hannover
Medical School, Hannover, Germany; 2Mosaiques Diagnostics GmbH,
Hannover, Germany; 3Ludwig-Maximilians-University, Munich, Ger-
many; 4University of Regensburg, Regensburg, Germany; 5Klinikum
Bremen Mitte gGmbH, Bremen, Germany.
We have recently published a polypeptide pattern speciﬁc for the
early diagnosis of acute graft versus host disease (aGvHD), based
on the application of capillary electrophoresis (CE) and mass spec-
trometry (MS). Here we report the application of aGvHD-speciﬁc
patterns to prospectively collected samples from 86 patients (45
AML, 14 ALL, 8 MM, 5 CLL, 5 SAA, 3 MDS, 3CML, 3 NHL).
Fifty-three patients were transplanted from matched unrelated
donors (MUD), 29 received stem cells from matched related do-
nors (MRD), 3 from haplo-identical donors and 1 was transplanted
from a syngeneic sibling. In the majority of the patients the GvHD
prophylaxis was methotrexate or mycophenolate and cyclosporin
A. Urine samples were collected on ice prior to conditioning,
weekly until discharge from the ward and monthly thereafter.
Immediate freezing of the samples avoids degradation of the pro-
teins/peptides. After thawing and removal of confounding sub-
stances like salts and of all molecules larger than 30 kDa, the
samples were loaded onto the CE, separated according to their
charge and, after ionization, directly analyzed in an electrospray-
ionization time-of-ﬂight (ESI-TOF)-MS. Between 500 and 2500
peptides and proteins were detected in individual samples. All data
generated are stored in a Microsoft MS database. The polypeptide
patterns speciﬁc for the early detection of acute GvHD were
applied to the data from the prospectively and blinded collected
samples. The outcome of these analyses was compared to the
clinical diagnosis of aGvHD, sepsis and CMV-reactivation. In 362
samples screened, 112 scored positive with the GvHD pattern.
Twenty-eight of those were false positive, mainly at the time of
conditioning, but only 3 were scored false negative. Thus the
sensitivity of the aGvHD pattern is about 96% with a 75% positive
prediction value, the speciﬁcity is about 89% with a negative
prediction value of 98%. Thus the application of the aGvHD
pattern for early recognition of acute GvHD is very useful for
predicting the development of aGvHD. Seven patients in the
prospective cohort have developed cGvHD so far and samples
were also scored with the aGvHD pattern. First results show that
in the majority of the patients the polypeptides excreted do not
correspond to those forming the aGvHD pattern. Taken together
our results demonstrate that the proteome analysis of body ﬂuids
collected from patients after HSCT maybe extremely useful for
diagnosis of complications.
HISTOCOMPATIBILITY/ALTERNATIVE
STEM CELL SOURCES
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UMBILICAL CORD BLOOD TRANSPLANTATION IN PEDIATRIC PA-
TIENTS: RESULTS OF THE PROSPECTIVE, MULTI-INSTITUTIONAL CORD
BLOOD TRANSPLANTATION STUDY (COBLT)
Kernan, N.A.1, Carter, S.L.2, Wagner, J.E.3, Baxter-Lowe, L.4,
Wall, D.5, Kapoor, N.6, Guinan, E.7, Wagner, E.8, Geller, N.8,
Kurtzberg, J.9 1Memorial Sloan-Kettering Cancer Center, New York,
NY; 2The EMMES Corporation, Rockville, MD; 3University of Min-
nesota, Minneapolis, MN; 4University of California, San Francisco, CA;
5Texas Transplant Institute, San Antonio, TX; 6Children’s Hospital of
Los Angeles, Los Angeles, CA; 7Dana Farber Cancer Institute, Boston,
MA; 8The National Heart, Lung and Blood Institute, Bethesda, MD;
9Duke University Medical Center, Durham, NC.
In 1996, NHLBI sponsored COBLT, a prospective study that
established 3 cord blood banks that banked8000 CBUs, and funded
28 transplant centers to participate in a clinical trial with the primary
endpoint of 180-day post-transplant overall survival (OS). The trial
enrolled 316 pediatric pts with median age 4.6 years (range 0.1-17.9),
61% M, 37% minorities, 44% CMV and 71% with a malignant
(malign) disease, who received a single CBU. CBUs had to be at least
4 of 6 HLA match (intermediate resolution A and B and high reso-
lution [HR] DRB1) and provide a total nucleated cell dose (TNC)
1.0  107/kg. Approximately 50% of Caucasian and Hispanic pts
received a CBU matched at HLA 5-6/6, but only 15% of African-
Americans and 36% of Asians were matched at HLA 5-6/6. HRHLA
types were retrospectively determined for HLA -A, -B, -DRB1 (292
pairs) and -C and -DQB1 (270 pairs). Only 30% of pairs were HR
HLA matched at 8-10 alleles. The median pre-cryopreservation
TNC and CD34 cell dose were 6.8  107/kg (range 1.5-50.4) and
2.3 105/kg (range 0.1-20.1), respectively. The cumulative incidence
(CINC) of neutrophil recovery (	500, day 42) and of platelet engraft-
ment (	50000, day 180) was 81% and 54%, respectively. By day
100, the CINC of grades II-IV aGVHD was 40%. The CINC of
cGVHD was 21% at 2 yrs. The probability of OS at 180 days
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